The role of fatty acid oxidation in the metabolic reprograming of activated T-cells

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Byersdorfer, Craig Alan ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AMP activated protein kinase; Fatty acid oxidation; Graft versus host disease; In vivo models; Oxidative phosphorylation; Reactive oxygen species (ROS); T cell metabolism

Indexed keywords

CD28 ANTIGEN; GLUCOSE TRANSPORTER 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

AEROBIC METABOLISM; AMINO ACID METABOLISM; AMINO ACID TRANSPORT; CELL DIFFERENTIATION; CELL METABOLISM; CITRIC ACID CYCLE; CYTOKINE PRODUCTION; FATTY ACID OXIDATION; GLYCOLYSIS; GRAFT VERSUS HOST REACTION; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNIZATION; MEMORY T LYMPHOCYTE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TH17 CELL; UPREGULATION;

EID: 84919496051     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00641     Document Type: Review

References (90)

1. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity (2011) 35:161-8. doi: 10.1016/j.immuni.2011.07.010
2. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol (2012) 12:749-61. doi:10.1038/nri3307
3. Badovinac VP, Haring JS, Harty JT. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. Immunity (2007) 26:827-41. doi:10.1016/j.immuni.2007.04.013
4. Yoon H, Kim TS, Braciale TJ. The cell cycle time of CD8+ T cells responding in vivo is controlled by the type of antigenic stimulus. PLoS One (2010) 5:e15423. doi:10.1371/journal.pone.0015423
5. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol (2005) 5:844-52. doi:10.1038/nri1710
6. Jones RG, Thompson CB. Revving the engine: signal transduction fuels T cell activation. Immunity (2007) 27:173-8. doi:10.1016/j.immuni.2007.07.008
7. Pollizzi KN, Powell JD. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. Nat Rev Immunol (2014) 14:435-46. doi:10.1038/nri3701
8. Pearce EL. Metabolism in T cell activation and differentiation. Curr Opin Immunol (2010) 22:314-20. doi:10.1016/j.coi.2010.01.018
9. Gerriets VA, Rathmell JC. Metabolic pathways in T cell fate and function. Trends Immunol (2012) 33:168-73. doi:10.1016/j.it.2012.01.010
10. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 342:1242454. doi:10.1126/science.1242454
11. Maciver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol (2013) 31:259-83. doi:10.1146/annurev-immunol-032712-095956
12. Brand K. Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. Biochem J (1985) 228:353-61.
13. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 16:769-77. doi:10.1016/S1074-7613(02)00323-0
14. Maciver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol (2008) 84:949-57. doi:10.1189/jlb.0108024
15. Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab (2014) 20:61-72. doi:10.1016/j.cmet.2014.05.004
16. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J Immunol (2008) 180:4476-86. doi:10.4049/jimmunol.180.7.4476
17. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, Maciver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol (2011) 186:3299-303. doi:10.4049/jimmunol.1003613
18. Yaqoob P, Calder PC. Glutamine requirement of proliferating T lymphocytes. Nutrition (1997) 13:646-51. doi:10.1016/S0899-9007(97)83008-0
19. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut (1987) 28:1221-7. doi:10.1136/gut.28.10.1221
20. Nakaya M, Xiao Y, Zhou X, Chang JH, Chang M, Cheng X, et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity (2014) 40:692-705. doi:10.1016/j.immuni.2014.04.007
21. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 478:197-203. doi:10.1038/nature10491
22. Sinclair LV, Rolf J, Emslie E, Shi YB, Taylor PM, Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol (2013) 14:500-8. doi:10.1038/ni.2556
23. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 136:521-34. doi:10.1016/j.cell.2008.11.044
24. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 281:1191-3. doi:10.1126/science.281.5380.1191
25. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 189:1363-72. doi:10.1084/jem.189.9.1363
26. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 4:762-74. doi:10.1038/nri1457
27. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature (2013) 504:446-50. doi:10.1038/nature12721
28. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science (2013) 341:569-73. doi:10.1126/science.1241165
29. Eberl M, Moser B. Monocytes and gammadelta T cells: close encounters in microbial infection. Trends Immunol (2009) 30:562-8. doi:10.1016/j.it.2009.09.001
30. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature (2013) 496:518-22. doi:10.1038/nature11868
31. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature (2013) 496:513-7. doi:10.1038/nature11984
32. Wulff P, Vallon V, Huang DY, Volkl H, Yu F, Richter K, et al. Impaired renal Na(+) retention in the sgk1-knockout mouse. J Clin Invest (2002) 110:1263-8. doi:10.1172/JCI0215696
33. Ardawi MS, Newsholme EA. Metabolism of ketone bodies, oleate and glucose in lymphocytes of the rat. Biochem J (1984) 221:255-60.
34. Frauwirth KA, Thompson CB. Regulation of T lymphocyte metabolism. J Immunol (2004) 172:4661-5. doi:10.4049/jimmunol.172.8.4661
35. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 460:103-7. doi:10.1038/nature08097
36. Hardie DG, Carling D. The AMP-activated protein kinase - fuel gauge of the mammalian cell? Eur J Biochem (1997) 246:259-73. doi:10.1111/j.1432-1033.1997.00259.x
37. Hardie DG. Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism. Proc Nutr Soc (2011) 70:92-9. doi:10.1017/S0029665110003915
38. O'Neill HM, Holloway GP, Steinberg GR. AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity. Mol Cell Endocrinol (2013) 366:135-51. doi:10.1016/j.mce.2012.06.019
39. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity (2012) 36:68-78. doi:10.1016/j.immuni.2011.12.007
40. Rolf J, Zarrouk M, Finlay DK, Foretz M, Viollet B, Cantrell DA. AMPKalpha1: a glucose sensor that controls CD8 T-cell memory. Eur J Immunol (2013) 43:889-96. doi:10.1002/eji.201243008
41. Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) (2009) 116:607-20. doi:10.1042/CS20080066
42. Buler M, Aatsinki SM, Izzi V, Uusimaa J, Hakkola J. SIRT5 is under the control of PGC-1alpha and AMPK and is involved in regulation of mitochondrial energy metabolism. FASEB J (2014) 28:3225-37. doi:10.1096/fj.13-245241
43. Vincent EE, Coelho PP, Blagih J, Griss T, Viollet B, Jones RG. Differential effects of AMPK agonists on cell growth and metabolism. Oncogene (2014). doi:10.1038/onc.2014.301
44. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J (2000) 348(Pt 3):607-14. doi:10.1042/0264-6021:3480607
45. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther (2010) 9:1092-9. doi:10.1158/1535-7163.MCT-09-1186
46. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 123:4479-88. doi:10.1172/JCI69589
47. Gubser PM, Bantug GR, Razik L, Fischer M, Dimeloe S, Hoenger G, et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat Immunol (2013) 14:1064-72. doi:10.1038/ni.2687
48. Nakada D, Saunders TL, Morrison SJ. Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature (2010) 468:653-8. doi:10.1038/nature09571
49. Wahl DR, Byersdorfer CA, Ferrara JL, Opipari AW Jr., Glick GD. Distinct metabolic programs in activated T cells: opportunities for selective immunomodulation. Immunol Rev (2012) 249:104-15. doi:10.1111/j.1600-065X.2012.01148.x
50. McNamee EN, Korns Johnson D, Homann D, Clambey ET. Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. Immunol Res (2013) 55:58-70. doi:10.1007/s12026-012-8349-8
51. Lum JJ, Bui T, Gruber M, Gordan JD, Deberardinis RJ, Covello KL, et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev (2007) 21:1037-49. doi:10.1101/gad.1529107
52. Dziurla R, Gaber T, Fangradt M, Hahne M, Tripmacher R, Kolar P, et al. Effects of hypoxia and/or lack of glucose on cellular energy metabolism and cytokine production in stimulated human CD4+ T lymphocytes. Immunol Lett (2010) 131:97-105. doi:10.1016/j.imlet.2010.02.008
53. Atkuri KR, Herzenberg LA, Niemi AK, Cowan T, Herzenberg LA. Importance of culturing primary lymphocytes at physiological oxygen levels. Proc Natl Acad Sci U S A (2007) 104:4547-52. doi:10.1073/pnas.0611732104
54. Tripmacher R, Gaber T, Dziurla R, Haupl T, Erekul K, Grutzkau A, et al. Human CD4(+) T cells maintain specific functions even under conditions of extremely restricted ATP production. Eur J Immunol (2008) 38:1631-42. doi:10.1002/eji.200738047
55. Glick GD, Rossignol R, Lyssiotis CA, Wahl D, Lesch C, Sanchez B, et al. Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol Exp Ther (2014) 351:298-307. doi:10.1124/jpet.114.218099
56. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol (2007) 7:340-52. doi:10.1038/nri2000
57. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet (2009) 373:1550-61. doi:10.1016/S0140-6736(09)60237-3
58. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant (2010) 45:1-11. doi:10.1038/bmt.2009.328
59. Gatza E, Wahl DR, Opipari AW, Sundberg TB, Reddy P, Liu C, et al. Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. Sci Transl Med (2011) 3:67ra68. doi:10.1126/scitranslmed.3001975
60. Kuhnke A, Burmester GR, Krauss S, Buttgereit F. Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment. Ann Rheum Dis (2003) 62:133-9. doi:10.1136/ard.62.2.133
61. Nagy G, Barcza M, Gonchoroff N, Phillips PE, Perl A. Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol (2004) 173:3676-83. doi:10.4049/jimmunol.173.6.3676
62. Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet (2012) 51:553-72. doi:10.2165/11633940-000000000-00000
63. Byersdorfer CA, Tkachev V, Opipari AW, Goodell S, Swanson J, Sandquist S, et al. Effector T cells require fatty acid metabolism during murine graft-versus-host disease. Blood (2013) 122:3230-7. doi:10.1182/blood-2013-04-495515
64. Shriver LP, Manchester M. Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis. Sci Rep (2011) 1:79. doi:10.1038/srep00079
65. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell (2005) 120:483-95. doi:10.1016/j.cell.2005.02.001
66. Sariban-Sohraby S, Magrath IT, Balaban RS. Comparison of energy metabolism in human normal and neoplastic (Burkitt's lymphoma) lymphoid cells. Cancer Res (1983) 43:4662-4.
67. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 208:1367-76. doi:10.1084/jem.20110278
68. Wahl DR, Petersen B, Warner R, Richardson BC, Glick GD, Opipari AW. Characterization of the metabolic phenotype of chronically activated lymphocytes. Lupus (2010) 19:1492-501. doi:10.1177/0961203310373109
69. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity (2013) 38:225-36. doi:10.1016/j.immuni.2012.10.020
70. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 25:9543-53. doi:10.1128/MCB.25.21.9543-9553.2005
71. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem (1995) 270:17513-20. doi:10.1074/jbc.270.29.17513
72. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol (2011) 13:1016-23. doi:10.1038/ncb2329
73. Maciver NJ, Blagih J, Saucillo DC, Tonelli L, Griss T, Rathmell JC, et al. The liver kinase B1 is a central regulator of T cell development, activation, and metabolism. J Immunol (2011) 187:4187-98. doi:10.4049/jimmunol.1100367
74. Lee J, Walsh MC, Hoehn KL, James DE, Wherry EJ, Choi Y. Regulator of fatty acid metabolism, acetyl coenzyme a carboxylase 1, controls T cell immunity. J Immunol (2014) 192:3190-9. doi:10.4049/jimmunol.1302985
75. Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci (2014) 39:347-54. doi:10.1016/j.tibs.2014.06.005
76. Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, et al. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med (2014) 20:1327-33. doi:10.1038/nm.3704
77. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 453:65-71. doi:10.1038/nature06880
78. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 146:772-84. doi:10.1016/j.cell.2011.07.033
79. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 476:346-50. doi:10.1038/nature10350
80. Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol (2013) 14:489-99. doi:10.1038/ni.2570
81. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis (2001) 32:1319-24. doi:10.1086/319985
82. Leather HL, Wingard JR. Infections following hematopoietic stem cell transplantation. Infect Dis Clin North Am (2001) 15:483-520. doi:10.1016/S0891-5520(05)70157-4
83. Doligalski CT, Benedict K, Cleveland AA, Park B, Derado G, Pappas PG, et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant (2014) 14:1328-33. doi:10.1111/ajt.12691
84. Grubbs JA, Baddley JW. Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis. Curr Rheumatol Rep (2014) 16:445. doi:10.1007/s11926-014-0445-4
85. Egli L, Lecoultre V, Theytaz F, Campos V, Hodson L, Schneiter P, et al. Exercise prevents fructose-induced hypertriglyceridemia in healthy young subjects. Diabetes (2013) 62:2259-65. doi:10.2337/db12-1651
86. Koutsari C, Mundi MS, Ali AH, Patterson BW, Jensen MD. Systemic free fatty acid disposal into very low-density lipoprotein triglycerides. Diabetes (2013) 62:2386-95. doi:10.2337/db12-1557
87. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell (2007) 11:37-51. doi:10.1016/j.ccr.2006.10.020
88. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med (2010) 2:31ra34. doi:10.1126/scitranslmed.3000677
89. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 491:364-73. doi:10.1038/nature11706
90. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 12:829-46. doi:10.1038/nrd4191